Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advanced Medical Isotope has entered into an agreement to further develop a proprietary brachytherapy treatment with Battelle, which operates the Pacific Northwest National Laboratory, and the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah.
Subscribe to our email newsletter
Advanced Medical Isotope (AMIC) proposes development of a proprietary concept for controlled delivery of yttrium-90 (Y-90) microspheres embedded in resorbable seed-shape materials for tissue-directed, high-dose intra-tumoral therapy. According to the company, the use of Y-90 will help to minimize the radiation dose to nearby normal tissues compared to x-rays from standard seeds.
This technology is said to be designed to improve the treatment of confined or non-resectable tumors and is based on fast-dissolving polymer-matrix chemistry. AMIC likely will seek new medical device approval from the FDA during 2009.
Robert Schenter, chief science officer at AMIC, said: “Using the same ultrasound-guided delivery methods and hardware familiar to seed implant surgeons, we hope to provide a better treatment option to the cancer patient. The ready availability of ultra-pure yttrium-90 provides an advantage.”